



Human Factor XI ELISA Kit

Vertrieb:

L O X O GmbH Immunbiologie Biochemie, Produkte und Systeme
Postfach 11 30 69215 Dossenheim
Telefon +49 (0) 62 21 - 86 80 23 **FAX** +49 (0) 62 21 - 86 80 255
E-Mail: info@loxo.de **Internet:** www.loxo.de

Assaypro LLC
30 Triad South Drive
St. Charles, MO 63304
T (636) 447-9175
F (636) 447-9475
www.assaypro.com

Hinweis/Note:

Der Packungsbeileger dient nur als erste Information.
Der relevante Packungsbeileger liegt der Ware bei.


The datasheet is only a first information.
The relevant datasheet is included with the product.

For any questions regarding troubleshooting or performing the assay, please contact our support team at support@assaypro.com.


Thank you for choosing Assaypro.

Assay Summary


Add 50 μ l of Standard/ Sample per well.
Incubate 2 hours.




Wash, then add 50 μ l of
Biotinylated Antibody per well.
Incubate 1 hour.



Wash, then add 50 μ l of
SP Conjugate per well.
Incubate 30 minutes.



Wash, then add 50 μ l of
Chromogen Substrate per well.
Incubate 15 minutes.



Add 50 μ l of Stop Solution per well.
Read at 450 nm immediately.

Assay Template

	1								
A	2								
B	3								
C	4								
D	5								
E	6								
F	7								
G	8								
H	9								
	10								
	11								
	12								

AssayMax Human Factor XI ELISA Kit

Catalog No. EF1011-1
Sample Insert/Reference Only

Introduction

Human coagulation factor XI (FXI), also called plasma thromboplastin antecedent, is a serine protease important for initiating the contact activation or intrinsic pathway of blood coagulation. FXI is present in plasma as a homodimer zymogen consisting of two identical polypeptide chains of 607 amino acids and 80 kDa each. FXI circulates in normal plasma at a concentration of 5 µg/ml. It is activated to form FXIa not only by factor XIIa through the contact pathway, but also by thrombin through feedback activation linking to tissue factor or extrinsic pathway. FXIa in turn cleaves factor IX and triggers a cascade event converting fibrinogen to a stable cross-linked fibrin clot formation (1-3). FXI also plays a role in the prevention of clot lysis from fibrinolysis (4). Congenital FXI deficiency is accompanied by mild and injury-related bleeding. Severe FXI deficiency is linked to low occurrence of ischemic stroke or venous thrombosis (5). In contrast, elevated FXI activity is a risk factor for stroke, venous thrombosis, and coronary artery disease (6-8). FXI is a new target for the treatment and prevention of thromboembolism.

Principle of the Assay

The AssayMax Human Factor XI (FXI) ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for detection of human factor XI in plasma, serum, and cell culture supernatant samples. This assay employs a quantitative sandwich enzyme immunoassay technique that measures FXI in less than 4 hours. A polyclonal antibody specific for FXI has been pre-coated onto a 96-well microplate with removable strips. FXI in standards and samples is sandwiched by the immobilized antibody and the biotinylated polyclonal antibody specific for FXI, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- **Prepare all reagents (working diluent buffer, wash buffer, standards, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.**

- **Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this protocol. However, the user should determine the optimal dilution factor.**
- **Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.**
- This kit is for research use only.
- The kit should not be used beyond the expiration date.
- The Stop Solution is an acidic solution.

Reagents

- **Human Factor XI Microplate:** A 96 well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against FXI.
- **Sealing Tapes:** Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- **Human Factor XI Standard:** Human FXI in a buffered protein base (50 ng, lyophilized, 2 vials).
- **Biotinylated Human Factor XI Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against FXI (140 μ l).
- **EIA Diluent Concentrate (10x):** A 10-fold concentrated buffered protein base (30 ml).
- **Wash Buffer Concentrate (20x):** A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- **Streptavidin-Peroxidase Conjugate (SP Conjugate):** A 100-fold concentrated (80 μ l).
- **Chromogen Substrate:** A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml).
- **Stop Solution:** A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store Standard, SP Conjugate, and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Diluent (1x) may be stored for up to 30 days at 2-8°C.

Other Supplies required

- Microplate reader capable of measuring absorbance at 450 nm.
- Pipettes (1-20 μ l, 20-200 μ l, 200-1000 μ l, and multiple channel).
- Deionized or distilled reagent grade water.

Sample Collection, Preparation and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x *g* for 10 minutes and collect supernatants. Dilute samples 1:600 into EIA Diluent or within the range of 1:300 to 1:1200, and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- **Serum:** Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 3000 x *g* for 10 minutes and remove serum. Dilute samples 1:600 into EIA Diluent or within the range of 1:300 to 1:1200, and assay. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **Cell Culture Supernatants:** Collect cell culture media and centrifuge at 3000 x *g* for 10 minutes at 4°C to remove debris. Collect supernatants and assay. Samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- **EIA Diluent Concentrate (10x):** If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the EIA Diluent Concentrate 1:10 with reagent grade water. Store for up to 30 days at 2-8°C.
- **Human Factor XI Standard:** Reconstitute the 50 ng (6.2 mU) of Human Factor XI Standard with 1 ml of EIA Diluent to generate a 50 ng/ml (6.2 mU/ml) standard solution. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the standard solution (50 ng/ml) 1:2 with EIA Diluent to produce standard solution of 25, 12.5, 6.25, 3.125, and 1.562 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Any remaining solution should be frozen at -20°C and used within 5 days.

Standard Point	Dilution	[FXI] (ng/ml)	[FXI] (mU/ml)
P1	Standard (50 ng/ml)	50.00	6.200
P2	1 part P1 + 1 part EIA Diluent	25.00	3.100
P3	1 part P2 + 1 part EIA Diluent	12.50	1.550
P4	1 part P3 + 1 part EIA Diluent	6.250	0.775
P5	1 part P4 + 1 part EIA Diluent	3.125	0.388
P6	1 part P5 + 1 part EIA Diluent	1.562	0.194
P7	EIA Diluent	0.000	0.000

- **Biotinylated Human Factor XI Antibody (50x):** Spin down the antibody briefly and dilute the desired amount of the antibody 1:50 with EIA Diluent. Any remaining solution should be frozen at -20°C.
- **Wash Buffer Concentrate (20x):** If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute the Wash Buffer Concentrate 1:20 with reagent grade water.
- **SP Conjugate (100x):** Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C.

Assay Procedure

- Prepare all reagents, working standards, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 µl of Human Factor XI Standard or sample per well. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash five times with 200 µl of Wash Buffer manually. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a machine, wash six times with 300 µl of Wash Buffer and then invert the plate, decanting the contents; hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor XI Antibody to each well and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of Streptavidin-Peroxidase Conjugate per well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.


- Add 50 μ l of Chromogen Substrate per well and incubate for about 15 minutes or till the optimal color density develops. Gently tap the plate to ensure thorough mixing and break the bubbles in the well with pipette tip.
- Add 50 μ l of Stop Solution to each well. The color will change from blue to yellow.
- Read the absorbance on a microplate reader at a wavelength of 450 nm **immediately**. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis


- Calculate the mean value of the duplicate or triplicate for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.

Standard Curve

- The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.



Human FXI Standard Curve



Performance Characteristics

- The minimum detectable level of FXI was typically ~ 1.5 ng/ml
- Intra-assay and inter-assay coefficients of variation were 5.1% and 7.1% respectively.
- Kit standard has been calibrated against WHO International Standard.

Linearity

Sample Dilution	Average Percentage of Expected Value	
	Plasma	Serum
1:300	90%	92%
1:600	99%	99%
1:1200	104%	103%

Recovery

Standard Added Value	3.13 – 25 ng/ml
Recovery %	84 – 112%
Average Recovery %	97.5%

Cross-Reactivity

Species	% Cross Reactivity
Canine	None
Bovine	None
Monkey	None
Mouse	None
Rat	None
Swine	None
Rabbit	None
Proteins	% Cross Reactivity
Factor XI	100%
Factor XIa	100%

Reference Value

- Normal plasma FXI levels range from 0.4 IU/ml – 1.6 IU/ml (3200 ng/ml – 12000 ng/ml).

References

- (1) Fujikawa K *et al.* (1986) *Biochemistry* 25: 2417-2424
- (2) Asakai R *et al.* (1987) *Biochemistry* 26: 7221-7228
- (3) Samuel D *et al.* (2007) *Proc. Natl. Acad. Sci. U.S.A.*104: 15693-15698
- (4) von dem Borne PA *et al.* (1995) *Blood* 86: 3035–3042
- (5) Salomon O *et al.* (2008) *Blood* 111: 4113-4117
- (6) Yang DT *et al.* (2006) *Am. J. Clin. Pathol.* 126: 411-415
- (7) Eichinger S *et al.* (2004) *Blood* 103: 3773-3776
- (8) Berliner JI *et al.* (2002) *Thromb Res.* 107: 55-60

Version 2.9